| Literature DB >> 34053675 |
Eero Castrén1, Lisa M Monteggia2.
Abstract
Neurotrophic factors, particularly BDNF (brain-derived neurotrophic factor), have been associated with depression and antidepressant drug action. A variety of preclinical and clinical studies have implicated impaired BDNF signaling through its receptor TrkB (neurotrophic receptor tyrosine kinase 2) in the pathophysiology of mood disorders, but many of the initial findings have not been fully supported by more recent meta-analyses, and more both basic and clinical research is needed. In contrast, increased expression and signaling of BDNF has been repeatedly implicated in the mechanisms of both typical and rapid-acting antidepressant drugs, and recent findings have started to elucidate the mechanisms through which antidepressants regulate BDNF signaling. BDNF is a critical regulator of various types of neuronal plasticities in the brain, and plasticity has increasingly been connected with antidepressant action. Although some equivocal data exist, the hypothesis of a connection between neurotrophic factors and neuronal plasticity with mood disorders and antidepressant action has recently been further strengthened by converging evidence from a variety of more recent data reviewed here.Entities:
Keywords: Antidepressants; BDNF; Ketamine; Mood disorders; Neurotrophins; TrkB
Mesh:
Substances:
Year: 2021 PMID: 34053675 DOI: 10.1016/j.biopsych.2021.05.008
Source DB: PubMed Journal: Biol Psychiatry ISSN: 0006-3223 Impact factor: 13.382